Search results
Added:
4 months ago
Explore advanced strategies for preventing and managing LVOT obstruction in transcatheter mitral valve replacement with Dr Mackram EleidThis presentation, part of Women As One's comprehensive Structural Interventions track, examines of a 90-year-old patient with severe mitral annular calcification, heart failure with preserved ejection fraction, and significant basal septal hypertrophy. Dr Eleid…
View more
Added:
9 months ago
EuroPCR 25 - First-in-human outcomes from the TRiCares Topaz Tricuspid Valve Replacement System in patents with tricuspid regurgitation (TR) show positive performance results and improved safety.We are joined by Dr Julien Dreyfus (Centre Cardiologique du Nord, Saint-Denis, FR) to discuss outcomes from the first-in-human, pivotal, multi-centre TRICURE EU study (NCT06581471; TRiCares) investigating…
View more
Added:
1 year ago
TCT Conference 2024 - Safety and efficacy outcomes of transcatheter aortic valve replacement (TAVR) compared to surgical aortic valve replacement (SAVR) in female patients with severe aortic stenosis.Dr Didier Tchétché (Clinique Pasteur, FR) joins us onsite at TCT Conference to discuss the pooled findings from the RHEIA (NCT04160130) and PARTNER 3 (NCT02675114) trials.RHEIA and PARTNER 3 are…
View more
Added:
1 year ago
TCT Conference 2024 - Safety and efficacy outcomes of transcatheter tricuspid valve replacement (TTVR) compared to optimal medical therapy for patients with severe tricuspid regurgitation (TR).Dr Susheel Kodali (Columbia University Medical Center, New York, US) joins us onsite at TCT Conference to discuss the findings from the TRISCEND II Trial (NCT04482062; Edwards Lifesciences).TRISCEND II is a…
View more
Innovation and Development of PHV TAVR
Added:
4 months ago
Review Article
Added:
11 months ago
ACC 2025 - First-in-human results from MyPEAK-1 show Tn-201 treatment in adults with Mybpc3-associated hypertropic cardiomyopathy was feasible and safe.Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at ACC 2025 to discuss phase Ib/2a results from the first-in-human, non-randomized study investigating the safety and early efficacy of Tn-201, an adeno-associated virus serotype 9 gene…
View more
Added:
1 year ago
TCT Conference 2024 - Safety and efficacy outcomes of transcatheter aortic valve replacement (TAVR) in addition to optimal heart failure therapy (OHFT) compared to OHFT alone in patients with heart failure and moderate aortic stenosis.Dr Nicolas M Van Mieghem (Erasmus University Medical Center, Rotterdam, NL) joins us onsite at TCT Conference to discuss the findings from TAVR UNLOAD (NCT02661451)…
View more
Added:
6 days ago
Source:
Transcatheter Academy
Seven-year follow-up data from the PARTNER 3 trial shows no significant difference in key outcomes between transcatheter aortic-valve replacement (TAVR) and surgical aortic-valve replacement (SAVR) for low-risk patients with severe, symptomatic aortic stenosis.¹ This long-term assessment provides further insight into valve durability and clinical outcomes, building on previous 5-year data which…
View more
Added:
2 weeks ago
Source:
Radcliffe Cardiology
An exploratory analysis of the EARLY TAVR trial has found that the benefits of early transcatheter aortic valve replacement (TAVR) for asymptomatic severe aortic stenosis (AS) are consistent, regardless of baseline left ventricular (LV) health.¹ This suggests that waiting for LV deterioration may not be the optimal strategy for timing intervention.MethodologyThis analysis used data from the EARLY…
View more
Gilbert Tang
Author